NEW TREATMENTS, NEW CHALLENGES: NEPHROTOXICITY ASSOCIATED TO NAXITAMAB IN PATIENTS WITH HIGH-RISK NEUROBLASTOMA

被引：0
|
作者：
Aguilar Rodriguez, Ana Cristina [1 ]
Arango Sancho, Pedro [1 ]
Munoz Perez, Juan Pablo [2 ]
Gorostegui Obanos, Maite [2 ]
Izurieta Pacheco, Ana Carolina
Codina Sampera, Elena [1 ]
Jimenez Moreno, Marta [1 ]
Calzada Banos, Yolanda [1 ]
Jimenez Garcia, Raquel [1 ]
Gomez Herrera, Bernat [1 ]
Madrid Aris, Alvaro [1 ]
Mora, Jaume [2 ]
机构：
[1] Hosp St Joan Deu, Pediat Nephrol, Esplugas de Llobregat, Spain
[2] Pediat Canc Ctr Barcelona, Barcelona, Spain
来源：
PEDIATRIC NEPHROLOGY | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
Su-3MP 105
引用
收藏
页码：S104 / S105
页数：2
相关论文
共 50 条
  • [1] NEW TREATMENTS, NEW CHALLENGES: NEPHROTOXICITY ASSOCIATED WITH NAXITAMAB IN HIGH-RISK NEUROBLASTOMA PATIENTS
    Gorostegui, Maite
    Munoz-Perez, Juan Pablo
    Aguilar-Rodriguez, Ana Cristina
    Sancho, Pedro Arango
    Izurieta, Ana Carolina
    Mora, Jaume
    PEDIATRIC BLOOD & CANCER, 2023, 70
  • [2] New treatments, new challenges: nephrotoxicity associated to naxitamab in patients with high-risk neuroblastoma
    Sancho, Pedro Arango
    Rodriguez, Ana Cristina Aguilar
    Espinoza, Yarima Lopez
    Marin, Emma Fortes
    Perez, Juan Pablo Munoz
    Obanos, Maite Gorostegui
    Banos, Yolanda Calzada
    Baez, Victor Alfonso Lopez
    Moreno, Marta Jimenez
    Sampera, Elena Codina
    Aris, Alvaro Madrid
    Mora, Jaume
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [3] New treatments, new challenges: nephrotoxicity associated to naxitamab in patients with high-risk neuroblastoma
    Arango Sancho, Pedro
    Aguilar Rodriguez, Ana Cristina
    Lopez Espinoza, Yarima
    Fortes Marin, Emma
    Munoz Perez, Juan Pablo
    Gorostegui Obanos, Maite
    Calzada Banos, Yolanda
    Lopez Baez, Victor Alfonso
    Jimenez Moreno, Marta
    Codina Sampera, Elena
    Madrid Aris, Alvaro
    Mora, Jaume
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I1857 - I1857
  • [4] Disease control in patients treated with naxitamab for refractory/relapsed high-risk neuroblastoma
    Mora, Jaume
    Chan, Godfrey C.
    Morgenstern, Daniel A.
    Amoroso, Loredana
    Nysom, Karsten
    Faber, Joerg
    Wingerter, Arthur
    Bear, Melissa
    Rubio-San-Simon, Alba
    Tornoe, Karen
    Koep, Sharif
    During, Maria
    Kushner, Brian H.
    CANCER RESEARCH, 2024, 84 (17)
  • [5] EFFICACY AND SAFETY OF NAXITAMAB IN PATIENT SUBGROUPS WITH HIGH-RISK NEUROBLASTOMA
    Mora, Jaume
    Chan, Godfrey Chi Fung
    Morgenstern, Daniel
    Amoroso, Loredana
    Nysom, Karsten
    Faber, Joerg
    Wingerter, Arthur
    Bear, Melissa
    Rubio San Simon, Alba
    Kushner, Brian
    Tornoe, Karen
    Christensen, Rene
    PEDIATRIC BLOOD & CANCER, 2023, 70
  • [6] PATTERN OF RELAPSE IN HIGH-RISK NEUROBLASTOMA (HR-NB) PATIENTS CONSOLIDATED WITH NAXITAMAB
    Rodriguez, Amalia Varo
    Vallejo, Elena Soques
    Gorostegui, Maite
    Zallo, Laura Andres
    Munoz Perez, Juan Pablo
    Heredia, Alicia Castaneda
    Mora, Jaume
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S231 - S231
  • [7] Evolving treatments in high-risk neuroblastoma
    Kumar, Abhinav
    Rocke, John P. J.
    Kumar, B. Nirmal
    EXPERT OPINION ON ORPHAN DRUGS, 2020, 8 (12): : 497 - 506
  • [8] Patterns of improvement following initial response in patients treated with naxitamab for relapsed/refractory high-risk neuroblastoma
    Mora, Jaume
    Chan, Godfrey C.
    Morgenstern, Daniel A.
    Amoroso, Loredana
    Nysom, Karsten
    Faber, Joerg
    Wingerter, Arthur
    Bear, Melissa
    Rubio-San-Simon, Alba
    Tornoe, Karen
    Duering, Maria
    Kushner, Brian H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Integrative discovery of treatments for high-risk neuroblastoma
    Elin Almstedt
    Ramy Elgendy
    Neda Hekmati
    Emil Rosén
    Caroline Wärn
    Thale Kristin Olsen
    Cecilia Dyberg
    Milena Doroszko
    Ida Larsson
    Anders Sundström
    Marie Arsenian Henriksson
    Sven Påhlman
    Daniel Bexell
    Michael Vanlandewijck
    Per Kogner
    Rebecka Jörnsten
    Cecilia Krona
    Sven Nelander
    Nature Communications, 11
  • [10] Integrative discovery of treatments for high-risk neuroblastoma
    Almstedt, Elin
    Elgendy, Ramy
    Hekmati, Neda
    Rosen, Emil
    Warn, Caroline
    Olsen, Thale Kristin
    Dyberg, Cecilia
    Doroszko, Milena
    Larsson, Ida
    Sundstrom, Anders
    Henriksson, Marie Arsenian
    Pahlman, Sven
    Bexell, Daniel
    Vanlandewijck, Michael
    Kogner, Per
    Jornsten, Rebecka
    Krona, Cecilia
    Nelander, Sven
    NATURE COMMUNICATIONS, 2020, 11 (01)
12345